Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 94% | 504.59 | 307 / 328 | 69% | 1.12 | 122 / 178 |
ovary | 100% | 814.03 | 180 / 180 | 58% | 0.90 | 249 / 430 |
kidney | 100% | 958.94 | 89 / 89 | 54% | 0.82 | 488 / 901 |
stomach | 99% | 634.47 | 354 / 359 | 51% | 0.79 | 146 / 286 |
bladder | 100% | 1000.19 | 21 / 21 | 47% | 0.80 | 239 / 504 |
lung | 100% | 1825.15 | 578 / 578 | 45% | 0.78 | 522 / 1155 |
esophagus | 99% | 763.58 | 1436 / 1445 | 45% | 0.64 | 83 / 183 |
intestine | 100% | 1055.20 | 966 / 966 | 41% | 0.63 | 216 / 527 |
brain | 99% | 612.50 | 2620 / 2642 | 39% | 0.57 | 277 / 705 |
uterus | 100% | 960.08 | 170 / 170 | 37% | 0.56 | 168 / 459 |
skin | 97% | 604.52 | 1760 / 1809 | 30% | 0.42 | 142 / 472 |
breast | 100% | 1348.85 | 459 / 459 | 23% | 0.33 | 260 / 1118 |
thymus | 100% | 930.61 | 653 / 653 | 23% | 0.35 | 137 / 605 |
liver | 100% | 825.05 | 226 / 226 | 22% | 0.32 | 89 / 406 |
adrenal gland | 99% | 652.69 | 255 / 258 | 7% | 0.07 | 15 / 230 |
prostate | 100% | 891.18 | 245 / 245 | 2% | 0.03 | 12 / 502 |
adipose | 100% | 1506.19 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 3018.77 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 3205.14 | 928 / 929 | 0% | 0 | 0 / 0 |
heart | 100% | 706.15 | 858 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 979.00 | 1330 / 1335 | 0% | 0 | 0 / 0 |
muscle | 85% | 330.27 | 684 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 66% | 1.17 | 19 / 29 |
tonsil | 0% | 0 | 0 / 0 | 20% | 0.26 | 9 / 45 |
eye | 0% | 0 | 0 / 0 | 1% | 0.01 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0009615 | Biological process | response to virus |
GO_0051607 | Biological process | defense response to virus |
GO_0035455 | Biological process | response to interferon-alpha |
GO_0035458 | Biological process | cellular response to interferon-beta |
GO_0098586 | Biological process | cellular response to virus |
GO_0060337 | Biological process | type I interferon-mediated signaling pathway |
GO_0046425 | Biological process | regulation of receptor signaling pathway via JAK-STAT |
GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
GO_0035456 | Biological process | response to interferon-beta |
GO_0140865 | Biological process | interleukin-22-mediated signaling pathway |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0004905 | Molecular function | type I interferon receptor activity |
GO_0019955 | Molecular function | cytokine binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0042018 | Molecular function | interleukin-22 receptor activity |
GO_0008269 | Molecular function | JAK pathway signal transduction adaptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | IFNAR2 |
Protein name | Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2) Interferon (Alpha, beta and omega) receptor 2 Interferon alpha and beta receptor subunit 2 |
Synonyms | IFNABR IFNARB |
Description | FUNCTION: Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) . Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response . Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another . The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (STAT1, STAT2 and STAT) . STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes . .; FUNCTION: [Isoform 3]: Potent inhibitor of type I IFN receptor activity. . |
Accessions | ENST00000342101.7 [P48551-3] C9JM33 ENST00000443073.5 ENST00000683941.1 [P48551-1] S6FRS2 F8WDE1 A0A804HLE8 H7C176 C9JCU0 ENST00000382238.6 ENST00000342136.9 [P48551-1] ENST00000404220.7 [P48551-2] ENST00000382264.7 [P48551-2] ENST00000447980.1 ENST00000682044.1 ENST00000417007.1 ENST00000413881.5 C9K067 P48551 Q9BUA0 |